JPS59118718A - Recovery of igm - Google Patents

Recovery of igm

Info

Publication number
JPS59118718A
JPS59118718A JP57226779A JP22677982A JPS59118718A JP S59118718 A JPS59118718 A JP S59118718A JP 57226779 A JP57226779 A JP 57226779A JP 22677982 A JP22677982 A JP 22677982A JP S59118718 A JPS59118718 A JP S59118718A
Authority
JP
Japan
Prior art keywords
igm
polyethylene glycol
precipitate
stirred
albumin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP57226779A
Other languages
Japanese (ja)
Inventor
Hideo Takeda
英夫 武田
Toru Sekiguchi
徹 関口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Inc
Original Assignee
Fujirebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Inc filed Critical Fujirebio Inc
Priority to JP57226779A priority Critical patent/JPS59118718A/en
Publication of JPS59118718A publication Critical patent/JPS59118718A/en
Pending legal-status Critical Current

Links

Abstract

PURPOSE:To prepare IgM easily, in high yield, by separating albumin and IgG fraction from blood plasma, extracting IgM from the above residue, adding polyethylene glycol to the extracted liquid, and recovering the produced precipitate. CONSTITUTION:Albumin and IgG fraction are separated from blood plasma by Cohn's ethanol fractionation and acrinol fractionation. The obtained residue is dispersed in a buffer solution such as acetic acid buffer solution having 4- 7 pH, or water, physiological saline water, etc., stirred, and separated into solid and liquid to extract IgM. The extracted liquid is adjusted to the protein concentration of 1-5% and pH of 4.3-6, preferably 4.5-5, mixed with polyethylene glycol, stirred at 10-20 deg.C, and left to stand for about a day, and the produced precipitate is recovered. The obtained precipitate is treated with dextran sulfate and calcium chloride to obtain IgM free from foreign materials.

Description

【発明の詳細な説明】 本発明はヒト免疫グロブリンの1種であるIgMを効率
よく回収する方法に関するものである。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a method for efficiently recovering IgM, which is a type of human immunoglobulin.

ヒト血漿を原料としてアルブミン及びIgGは工業的規
模で生産されているが、IgMは血漿中の含有量が少な
く、マだ量産されるにいたっていない。
Albumin and IgG are produced on an industrial scale using human plasma as a raw material, but IgM is not mass-produced because the content of IgM in plasma is small.

本発明者らはこの従来廃棄されていた、血漿からアルブ
ミン及びIgG分画を分離した残渣がら新たにIgMを
容易にかつ高収率で取得する方法を開発しだのである。
The present inventors have developed a new method for easily obtaining IgM at a high yield from the residue of albumin and IgG fractions separated from plasma, which had previously been discarded.

従来、I gMの取得方法はいくつか報告されており、
血漿を出発原料とするものについても、例えばコーン分
画■をアクリノール処理する方法(特開昭55−903
6号)、イオン交換クロマトグラフィーで分離する方法
などいくつかの方法があるが、いずれも精製工程が長く
、操作面と収率面の両方で問題になっていた。
Conventionally, several methods for obtaining IgM have been reported.
For those using plasma as a starting material, for example, the method of treating Cohn's fraction
There are several methods, including separation using ion exchange chromatography (No. 6), but all of them involve long purification steps, which pose problems in terms of both operation and yield.

本発明者らは、IgMを安価かつ容易に取得する方法を
開発すべく鋭意検討の結果、血漿からアルブミン及びI
gG分画を分離した残渣に対するポリエチレングリコー
ルの精製効果が極めて大きいことを見出し、これに基い
て本発明を完成するに至った。
As a result of intensive studies to develop a method to obtain IgM at low cost and easily, the present inventors discovered that albumin and IgM can be obtained from plasma.
It was discovered that polyethylene glycol has an extremely large purifying effect on the residue obtained by separating the gG fraction, and based on this finding, the present invention was completed.

すなわち本発明は、血漿からアルブミン及びIgG分画
を分離した残渣からIgMを抽出した抽出液にポリエチ
レングリコールを加え、生成した沈澱物を回収すること
を特徴とするIgMの回収方法に関するものである。
That is, the present invention relates to a method for recovering IgM, which is characterized by adding polyethylene glycol to an extract obtained by extracting IgM from a residue obtained by separating albumin and IgG fractions from plasma, and collecting the generated precipitate.

血漿からアルブミン及びIgG分画の分離方法は:+ 
−7(7) xタノール分画法、アクリノール分画法、
など棟々知られているがその種類を問わない。この聯−
画分を分離した残渣はIgMが含まれているものでなけ
ればならないことはいう壕でもない。
The method for separating albumin and IgG fractions from plasma is: +
-7(7) x Tanol fractionation method, acrinol fractionation method,
There are many types of buildings, but the type does not matter. This couple-
It is not necessarily the case that the residue after separating the fractions must contain IgM.

このような残渣の例としては、コーンのエタノール分画
法の場合には、分画■及びIV−1など、そしてアクリ
ノール分画法の場合には沈澱■などを挙げることができ
る。
Examples of such residues include fractions ① and IV-1 in the case of Cohn's ethanol fractionation method, and precipitate ③ in the case of the acrinol fractionation method.

残渣からIgMを抽出する方法は公知の方法に従えばよ
く、例えばpH4〜7程度の酢酸緩衝液、リン酸緩衝液
等の緩衝液、あるいは水、生理食塩溶液などに残渣を投
入して懸濁させ、5℃で4時間程度攪拌してから固液分
離すればよい。
IgM can be extracted from the residue by following a known method, for example, by suspending the residue in a buffer such as acetate buffer or phosphate buffer with a pH of about 4 to 7, or in water, physiological saline, etc. After stirring at 5° C. for about 4 hours, solid-liquid separation may be performed.

抽出液は、蛋白濃度を1〜5%程度、そして声を43〜
6程度、好捷しくは45〜50程度に調整してからポリ
エチレングリコールを投入する。
The extract has a protein concentration of 1 to 5% and a voice of 43 to 5%.
After adjusting the temperature to about 6, preferably about 45 to 50, add polyethylene glycol.

このPH調整はポリエチレングリコール投入後に行なっ
てもよい。ポリエチレングリコールを投入する前に必要
によシその他の前処理を施してもよいことはいうまでも
ない。
This pH adjustment may be performed after adding polyethylene glycol. It goes without saying that prior to adding polyethylene glycol, other pretreatments such as rinsing may be performed as necessary.

ポリエチレングリコールは分子量が2000〜1000
0程度のものがよく、6000前後のものが特に好適で
ある。添加量は、分子量6000のものの場合には、3
〜10%程度、特に4〜7φ程度が適当である。他の分
子量のものを用いる場合には予め試験を行なって適当な
添加量を定めればよい。
Polyethylene glycol has a molecular weight of 2000-1000
A value of about 0 is good, and a value of about 6000 is particularly preferable. The amount added is 3 if the molecular weight is 6000.
~10%, particularly approximately 4 to 7φ is appropriate. When using substances with other molecular weights, tests may be conducted in advance to determine the appropriate amount to be added.

ポリエチレングリコールの添加後は10〜20℃で攪拌
混合し、その後−昼夜程度静置して生成した沈澱物を回
収する。回収方法は固液分離の常法によって行なえばよ
く、遠心分離などで分離すればよい。
After adding polyethylene glycol, the mixture is stirred and mixed at 10 to 20°C, and then left to stand for about day and night to collect the formed precipitate. The recovery method may be any conventional solid-liquid separation method, such as centrifugation.

得られた沈澱物にはまだリポ蛋白、変性蛋白及びある種
の不安定な物質が多量に含まれているか、この沈澱物を
デキストラン硫酸及び塩化カルシウムで処理することに
よってこれらの爽雑物を容易に除去することができる。
The resulting precipitate still contains large amounts of lipoproteins, denatured proteins, and certain unstable substances, or these impurities can be easily removed by treating the precipitate with dextran sulfate and calcium chloride. can be removed.

処理方法としては、まず沈澱を蛋白濃度2〜25%程度
に溶解し、この溶液をpH5〜8程度にして、0.00
1〜003チ程度のデキストラン硫酸及び0.01〜0
.1 M程度の塩化カルシウムを添加する。それから、
30分間程度攪拌して遠心分離し、沈澱物を除去すれば
よい。
The treatment method is to first dissolve the precipitate to a protein concentration of about 2 to 25%, adjust the pH of this solution to about 5 to 8, and adjust the pH to 0.00.
Dextran sulfate of about 1-003% and 0.01-0
.. Add about 1M calcium chloride. after that,
The precipitate may be removed by stirring and centrifuging for about 30 minutes.

本発明の方法は従来廃棄されていた残渣からIgMを容
易にかつ高収率で取得しうるものであり、ポリエチレン
グリコール処理を1回行なうだけで、その後、例えばデ
キストラン硫酸及び塩化カルシウム処理を行なうことに
よってかってない高収率で高純度のIgMを回収するこ
とができる。
The method of the present invention allows IgM to be obtained easily and in high yield from residues that were conventionally discarded, and requires only one treatment with polyethylene glycol, followed by treatment with, for example, dextran sulfate and calcium chloride. High purity IgM can be recovered at an unprecedentedly high yield.

次に、PH及びポリエチレングリコールの添加量と、I
gMの回収率及び純度の向上を測定1.た偵察実験の結
果を示す。
Next, the amount of addition of PH and polyethylene glycol, and the amount of I
Measurement of improvement in gM recovery and purity 1. The results of the reconnaissance experiment are shown below.

実験方法としては、−20℃に凍結保存しておいだコー
ン分画■のペースト25&にPH4,0の0.1M酢酸
すl−IJウム緩衝溶液75m7!を加えて5時間攪拌
し、遠心分離して1gM抽出液を得た。この抽出液を蛋
白濃度が18係でPHが下表に示す如くなるように調整
し、ポリエチレングリコール(PEG)6000を下表
に示す濃度になるように添加した。
The experimental method involved adding 25ml of a paste of Cohn's fraction (1) that had been frozen and stored at -20°C to 75m7 of a 0.1M sodium acetate buffer solution with a pH of 4.0. was added, stirred for 5 hours, and centrifuged to obtain a 1 gM extract. This extract was adjusted so that the protein concentration was 18 and the pH was as shown in the table below, and polyethylene glycol (PEG) 6000 was added to the solution so that the concentration was as shown in the table below.

10〜20℃で2時間攪拌後−昼夜放置し、遠心分離し
て上清液を集め分析したところ、下・表に示す如き結果
が得られた。
After stirring for 2 hours at 10-20°C, the mixture was left to stand day and night, centrifuged, and the supernatant liquid was collected and analyzed, and the results shown in the table below were obtained.

なお、表の各粋の数字の上段は(上清液の総蛋白量/原
液の総蛋白量)X100を表わしており、下段は(上清
液のIgM量/原液のIgM量) x 1o。
The upper row of each number in the table represents (total protein amount of supernatant solution/total protein amount of stock solution) x 100, and the lower row represents (IgM amount of supernatant solution/IgM amount of stock solution) x 1o.

を表わしている。表から明らかな如く、P14は43〜
6程度、特に45〜50程度がよく、PEG 6000
の濃度は3〜10襲程度、特に4〜7係程度が適当であ
った。
It represents. As is clear from the table, P14 is 43~
About 6, especially about 45 to 50 is good, PEG 6000
The appropriate concentration was about 3 to 10 parts, especially about 4 to 7 parts.

実施例 一20℃に凍結保存しておいたコーン分画■1000.
9に声40のO,]、 M酢酸ナトリウム緩衝液3、β
を加え、5℃で4時間攪拌した。これにノ・イフロスー
・や−セル100.!7を添加して濾過し、抽出液を得
だ。抽出液にpH4,5−の0. I M酢酸ナトリウ
ム緩衝液を加えて蛋白濃度を18係にし、10 NNa
OHでPHを45に調整した。これに、ポリエチレング
リコール6000を5 w/v %になるように添加し
て15℃で2時間攪拌し、−昼夜静置した。遠心分離し
て沈澱物を回収し、この沈澱物を1にの0.1 Mリン
酸緩衝液(pH6,5)に溶解した。この溶液に塩化カ
ルンウムを0.OIMになるように、そしてデキストラ
ン硫酸を0.0 O1%になるように添加し、室温で3
0分間攪拌した。生成しプこ沈澱物を遠心分離して1g
M溶液を得だ。
Example 1 Cohn fraction stored frozen at 20°C ■1000.
9 to 40 O, ], M sodium acetate buffer 3, β
was added and stirred at 5°C for 4 hours. This is 100 cells. ! 7 was added and filtered to obtain an extract. The extract has a pH of 4.5-0. IM sodium acetate buffer was added to bring the protein concentration to 18%, and 10 NNa
The pH was adjusted to 45 with OH. To this, polyethylene glycol 6000 was added at a concentration of 5 w/v %, stirred at 15° C. for 2 hours, and allowed to stand overnight. The precipitate was collected by centrifugation, and the precipitate was dissolved in 0.1 M phosphate buffer (pH 6.5). Add 0.0% of carunium chloride to this solution. Add dextran sulfate to 0.0 OIM and dextran sulfate to 1% OIM, and incubate at room temperature for 30 minutes.
Stirred for 0 minutes. The resulting precipitate was centrifuged and weighed 1 g.
Obtain M solution.

この1gM溶液にはIgMが28g含まれておシ、原料
の被−ストからの収率ば65係であった。また、IgM
の蛋白純度は85%であシ、−、マクログロブリン1係
及び75%のIgAが含捷れていることを放射免疫拡散
法によって確認した。
This 1 gM solution contained 28 g of IgM, and the yield from the raw material was 65%. Also, IgM
The protein purity of the protein was 85%, and it was confirmed by radioimmunodiffusion that it contained 75% of IgA and macroglobulin 1.

特許出願人  富士臓器製薬株式会社Patent applicant: Fuji Organ Pharmaceutical Co., Ltd.

Claims (1)

【特許請求の範囲】[Claims] 血漿からアルブミン及びIgiG分画を分離した残渣か
らIgMを抽出した抽出液にポリエチレングリコールを
加え、生成した沈澱物を回収することを特徴とするIg
Mの回収方法。
Ig characterized in that polyethylene glycol is added to an extract obtained by extracting IgM from a residue obtained by separating albumin and IgiG fractions from plasma, and the resulting precipitate is collected.
How to collect M.
JP57226779A 1982-12-27 1982-12-27 Recovery of igm Pending JPS59118718A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57226779A JPS59118718A (en) 1982-12-27 1982-12-27 Recovery of igm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57226779A JPS59118718A (en) 1982-12-27 1982-12-27 Recovery of igm

Publications (1)

Publication Number Publication Date
JPS59118718A true JPS59118718A (en) 1984-07-09

Family

ID=16850473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57226779A Pending JPS59118718A (en) 1982-12-27 1982-12-27 Recovery of igm

Country Status (1)

Country Link
JP (1) JPS59118718A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0278635A (en) * 1988-07-27 1990-03-19 Biotest Ag Polyclonal immunoglobulin for intravenous administration containing igm and its preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0278635A (en) * 1988-07-27 1990-03-19 Biotest Ag Polyclonal immunoglobulin for intravenous administration containing igm and its preparation

Similar Documents

Publication Publication Date Title
Surgenor et al. The Separation of Choline Esterase, Mucoprotein, and Metal-Combining Protein into Subfractions of Human Plasma1a, b, c
US4203891A (en) Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US3808189A (en) Isolation of gamma globulin preparations enriched in iga and igm using polyethylene glycol
US4087415A (en) Antithrombin III
EP0249483B1 (en) Method of producing substantially pure albumin
JPH08509746A (en) Purification of plasma proteins
US4348316A (en) New protein PP15, a process for its preparation and its use
JPS59222420A (en) Manufacture of viii factor containing medicine
US4104125A (en) Process for producing human lysozyme
JPS6059212B2 (en) How to obtain factor 8
NO147820B (en) PROCEDURE FOR THE ISOLATION AND EXTRACTION OF PROTEIN HORMONES DETERMINED FROM HUMAN HYPOPHYSE TISSUE
Miquel et al. Isolation and purification of human biliary vesicles with potent cholesterol-nucleation-promoting activity
JPS6078999A (en) Purification of hbs antigen
CA2274241C (en) A process for purifying apolipoprotein a or apolipoprotein e from human plasma
Gotto et al. Human serum beta-lipoprotein: preparation and properties of a delipidated, soluble derivative
WO2014194362A1 (en) Process for preparing apolipoprotein a-i (apo a-i)
Derechin Purification of human plasminogen
JPS59118718A (en) Recovery of igm
JPH0236193A (en) Purification of 168kd protein from mycoplasma newmoniae
US4197238A (en) Method of preparation of human albumin using polyethylene glycol
Deisseroth et al. The purification and crystallization of beef erythrocyte catalase
US4588685A (en) Process for the preparation of a new-type active substance selectively inhibiting food intake
JPS6143330B2 (en)
JPH06228197A (en) Method for fractionating gamma-livetin from egg yolk
PL93587B1 (en)